Virtual Reality Exposure Therapy for Gambling Disorder (VIRET-GAD)

Virtual Reality Exposure Therapy for Gambling Disorder: Randomized Controlled Trial

Gambling disorder (GD) is recognized as an addictive disorder in the DSM-5. Craving is a core phenomenon in addiction that can lead to relapse in problem gambling for pathological gamblers. Exposure Therapy (ET) focuses on craving in addiction treatment. ET in Cognitive-Behavioral Therapy (CBT) is based on classical conditioning that addresses the association between contextual cues and the craving response. ET helps the patient to reduce craving when faced with cues triggering craving. ET includes in vivo exposure and imaginal exposure. The literature recommends being as close as possible to the context of addiction to facilitate the extinction of craving but in vivo ET is complicated to perform. For GD, in outpatient consultation, bringing a patient to a casino presents obstacles (e.g., time, human and financial cost, agreement with casino for therapy).

The study will be to assess the effectiveness of Virtual Reality Exposure Therapy (VRET) in a virtual gambling environment. Various trials show that VRET is no more or less effective than classical ET in CBT but has other advantages for motivation to treatment. This research aims to compare efficacy between CBT with VRET and CBT with imaginal exposure for treatment of GD in a multicenter, randomized, controlled, non-inferiority clinical trial.

Study Overview

• Status: Not yet recruiting
• Conditions: Gambling Disorder
• Intervention / Treatment: Other: cognitive-behavioral therapy for gambling disorder; Other: virtual reality exposure therapy focus on gambling cues; Other: imaginal exposure therapy focus on gambling cues

Detailed Description

Main aim:

Show, within patients seeking care for GD, that VRET integrated with CBT is non-inferior to imaginal ET integrated with CBT on GD symptom reduction at the end of 12 treatment sessions.

Secondary objectives:

1. Show that VRET integrated with CBT is non-inferior to imaginal ET integrated with CBT on GD symptom reduction during the first 12 months post-treatment.
2. Compare the effect of the two therapeutic strategies on GD symptoms (measured by complementary assessments to that used in the main aim), at the end of treatment and during the first 12 months post-treatment.
3. Show the efficacy of VRET integrated with CBT compared to imaginal ET integrated with CBT on gambling behavior, craving, and gambling-related cognitions at the end of treatment and during the first 12 months post-treatment.
4. Show the efficacy of VRET integrated with CBT compared to imaginal ET integrated with CBT on the evolution of anxiety and depressive symptoms at the end of treatment and during the first 12 months post-treatment.
5. Compare the quality of the two therapeutic strategies at the end of treatment.

• Study Type: Interventional
• Enrollment (Estimated): 124
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Pierre TAQUET, PhD; Phone Number: +33 0320445838; Email: pierre.taquet@chru-lille.fr

Study Locations

• France
  • Amiens, France
    • CHU Amiens-Picardie
    • Principal Investigator: Alain DERVAUX, MD,PhD
  • Boulogne-sur-Mer, France
    • CH Boulogne sur mer CSAPA
    • Principal Investigator: Fréderic TEISSIERE, MD
  • Caen, France
    • CHU de Caen
    • Principal Investigator: Nicolas CABE, MD
  • Lille, France, 59000
    • Hôpital Fontan, CHU lille
    • Principal Investigator: Olivier COTTENCIN, MD,PhD
  • Lomme, France
    • Assoriation Cédragir Lomme CSAPA
    • Sub-Investigator: Stéphanie Lienard
  • Montreuil sur Mer, France
    • CH de l'arrondissement de Montreuil / CSAPA
    • Sub-Investigator: Mathieu LAWNICZAK
  • Rouen, France
    • CHU Rouen
    • Principal Investigator: Olivier GUILLIN, MD, PhD
  • Saint-Amand-les-Eaux, France
    • CH de Saint Amand les Eaux
    • Principal Investigator: Charles LESCUT, MD
  • Seclin, France
    • CH Seclin Carvin CSAPA
    • Principal Investigator: Pierre TAQUET, PhD
  • Valenciennes, France
    • Association GREID ValenciennesCSAPA
    • Sub-Investigator: Ines Roux

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Seek treatment for GD within one of health care facilities participating in the research (first request for treatment and not patients already receiving treatment for gambling disorder in the care center).
• Meet a current diagnosis of gambling disorder according to DSM-5 criteria and with a South Oaks Gambling Screen (SOGS) score ≥ 5
• Meet a casino gambling behavior with a casino gambling frequency ≥ 1 time every two months during the last 12 months
• Have a sufficient understanding of French for therapy
• Beneficiary of the French social security system
• Give an informed consent to participate
• Willing to comply with all study procedures and duration

Exclusion Criteria:

• Visual disturbance making impossible the use of virtual reality equipment (e.g. advanced retinal degeneration, central scotoma, age-related macular degeneration)
• Pregnant woman
• Minor or adult under guardianship, conservatorship, under judicial protection, persons deprived of their liberty
• Balance disorder (e.g. cerebellar disorder, inner ear disorder)
• Photosensitive epilepsy
• Refusal to participate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CBT with VRET	Other: cognitive-behavioral therapy for gambling disorder; 6 sessions of cognitive-behavioral therapy for gambling disorder; Other: virtual reality exposure therapy focus on gambling cues; 6 sessions of virtual reality exposure therapy focus on gambling cues
Active Comparator: CBT with imaginal ET	Other: cognitive-behavioral therapy for gambling disorder; 6 sessions of cognitive-behavioral therapy for gambling disorder; Other: imaginal exposure therapy focus on gambling cues; 6 sessions of imaginal exposure therapy focus on gambling cues

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in South Oaks Gambling Screen (SOGS) between baseline and end of treatment (12 sessions, 6 months)	The SOGS is a 20-item instrument used to screen for pathological gambling. The SOGS is scored by summing the number of items endorsed out of 20 and a cut score of 5 or more indicates a probable pathological gambling. The score ranges from 0 to 20.	at the end of treatment (an average of 6 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in South Oaks Gambling Screen (SOGS) between baseline and follow-up at 3, 6 and 12 months after the end of treatment	The SOGS is a 20-item instrument used to screen for pathological gambling. The SOGS is scored by summing the number of items endorsed out of 20 and a cut score of 5 or more indicates a probable pathological gambling. The score ranges from 0 to 20.	at baseline, and through study completion, an average of 18 months
Change in gambling disorder symptoms between baseline, end of treatment and follow-up assessed by the following criteria: number of DSM-5 criteria for GD	Nine criteria for gambling disorder are described in DSM-5. The endorsement of 4-5 criteria means the presence of a mild gambling disorder, 6-7 criteria a moderate gambling disorder and 8-9 criteria a severe gambling disorder. The score ranges from 0 to 9 criteria.	at baseline, and through study completion, an average of 18 months
Change in gambling disorder symptoms between baseline, end of treatment and follow-up assessed by the following criteria: Problem Gambling Severity Index (PGSI)	The PGSI consists of nine items to assess level of risk for problem gambling. Cut-off scores are 1-2 for low-risk gamblers, 3-7 for moderate-risk gamblers and 8 or more for problem-gamblers. Non-problem gamblers correspond to 0. The score ranges from 0 to 27.	at baseline, and through study completion, an average of 18 months
Change in gambling behavior assessed by gambling frequency during the last month		at baseline, and through study completion, an average of 18 months
Change in gambling behavior assessed by amount of money spent in gambling during the last month		at baseline, and through study completion, an average of 18 months
Change in gambling behavior assessed by time spent gambling during the last month		at baseline, and through study completion, an average of 18 months
Change in frequency subscale of gambling Craving Experience Questionnaire (g-CEQ)	The frequency subscale of gambling Craving Experience Questionnaire assesses the frequency of craving for gambling during the last week. This questionnaire consists of nine items. A high score means a high frequency of craving during the last week. The score ranges from 0 to 90.	at baseline, and through study completion, an average of 18 months
Change in craving reactivity to gambling cues		at baseline, and through study completion, an average of 18 months
Number of craving episodes using daily craving assessed by participants		up to 6 months during the treatment
Cumulative duration of craving episodes using daily craving assessed by participants		up to 6 months during the treatment
Change in gambling-related cognitions assessed by Gambling-Related Cognitions Scale (GRCS)	The French version of the Gambling-Related Cognitions Scale consists of 23 items to assess various cognitions related to gambling. A high score means that gambling-related cognitions are typical cognitions of problem gamblers. The score ranges from 23 to 161.	at baseline, and through study completion, an average of 18 months
Change in depressive symptoms assessed by Beck Depression Inventory short-form (BDI-SF)	Beck Depression Inventory short-form consists of 13 items to assess depressive symptoms. A high score means a high level of depressive symptoms. The score ranges from 0 to 39.	at baseline, and through study completion, an average of 18 months
Change in anxiety symptoms assessed by State-Trait Anxiety Inventory (STAI)	State-Trait Anxiety Inventory consists of 20 items to assess state-anxiety and 20 items to assess trait-anxiety. A high score means a high level of anxiety symptoms. The score ranges from 20 to 80 both for state-anxiety and trait-anxiety.	at baseline, and through study completion, an average of 18 months
Rate of patients who attended the 12 sessions (6 months)	Quality of the two therapeutic strategies	up to 6 months during the treatment

Collaborators and Investigators

• Sponsor: University Hospital, Lille
• Collaborators: Ministry of Health, France
• Investigators: Principal Investigator: Pierre TAQUET, PhD, University Hospital, Lille

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2024
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: June 29, 2020
• First Submitted That Met QC Criteria: July 8, 2020
• First Posted (Actual): July 13, 2020

Study Record Updates

• Last Update Posted (Actual): January 26, 2024
• Last Update Submitted That Met QC Criteria: January 25, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: cognitive behavioral therapy; virtual reality; CBT; Exposure therapy; pathological gambling
• Additional Relevant MeSH Terms: Mental Disorders; Disruptive, Impulse Control, and Conduct Disorders; Gambling
• Other Study ID Numbers: 2020_02; 2020-A02710-39 (Other Identifier: ID-RCB number, ANSM)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No